Bliss GVS Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE416D01022
  • NSEID: BLISSGVS
  • BSEID: 506197
INR
481.35
6.8 (1.43%)
BSENSE

Jun 18

BSE+NSE Vol: 9.59 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Innova Captab
Senores Pharma.
Bliss GVS Pharma
Advanced Enzyme
RPG LifeScience.
Gufic BioScience
FDC
Guj. Themis Bio.
Orchid Pharma
Aarti Pharma
Zota Health Care
Why is Bliss GVS Pharma Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Poor long term growth as Net Sales has grown by an annual rate of 9.94% and Operating profit at 7.87% over the last 5 years
3
Positive results in Mar 26
  • PAT(Q) At Rs 35.56 cr has Grown at 128.8%
  • ROCE(HY) Highest at 16.80%
  • DEBT-EQUITY RATIO(HY) Lowest at 0.02 times
4
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 24-Mar-26 and has generated 132.7% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST, DOW and OBV
5
With ROE of 11, it has a Very Expensive valuation with a 4.2 Price to Book Value
  • The stock is trading at a fair value compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 244.07%, its profits have risen by 55% ; the PEG ratio of the company is 0.7
6
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -4.84% over the previous quarter and collectively hold 15.49% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Bliss GVS Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bliss GVS Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Bliss GVS Pharma
244.07%
4.01
60.81%
Sensex
-4.95%
-0.37
13.26%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
9.94%
EBIT Growth (5y)
7.87%
EBIT to Interest (avg)
14.32
Debt to EBITDA (avg)
0.68
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.74
Tax Ratio
28.94%
Dividend Payout Ratio
6.25%
Pledged Shares
0
Institutional Holding
15.49%
ROCE (avg)
12.39%
ROE (avg)
9.73%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
39
Industry P/E
34
Price to Book Value
4.22
EV to EBIT
37.43
EV to EBITDA
29.79
EV to Capital Employed
4.67
EV to Sales
5.27
PEG Ratio
0.71
Dividend Yield
0.21%
ROCE (Latest)
12.48%
ROE (Latest)
10.95%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
PAT(Q)

At Rs 35.56 cr has Grown at 128.8%

ROCE(HY)

Highest at 16.80%

DEBT-EQUITY RATIO(HY)

Lowest at 0.02 times

NET SALES(Q)

Highest at Rs 256.99 cr

PBDIT(Q)

Highest at Rs 44.44 cr.

PBT LESS OI(Q)

Highest at Rs 33.76 cr.

-4What is not working for the Company
INTEREST(Q)

At Rs 2.01 cr has Grown at 34.90%

Loading Valuation Snapshot...
Here's what is working for Bliss GVS Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 33.76 cr has Grown at 196.92%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 35.56 cr has Grown at 128.8%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Debt-Equity Ratio - Half Yearly
Lowest at 0.02 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales - Quarterly
Highest at Rs 256.99 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 256.99 cr has Grown at 29.80%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 44.44 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 33.76 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Here's what is not working for Bliss GVS Pharma
Interest - Quarterly
At Rs 2.01 cr has Grown at 34.90%
Quarter on Quarter (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)